Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World April 2011	Molecular Obesity is Weighing Down Drug Discovery Medicinal chemistry's quest for potent drug candidates has resulted in molecules that are too large and too lipophilic for their own good.
Chemistry World December 2008	Column: In the pipeline I've worked on two drug discovery efforts (one right after the other, as fate would have it) whose final compounds differed by essentially one methyl group from the starting points of each project.
Chemistry World October 2009	Column: In the pipeline Derek Lowe discusses the problem of leaning too heavily on favorite reactions
Chemistry World November 27, 2013 Derek Lowe	Rolling boulders uphill A lot of preclinical projects don't even get off the ground, and many that do still never deliver anything to the development groups.
Chemistry World December 1, 2014 Derek Lowe	Progress at the pace of the slowest Chemistry is a means to an end in drug research, not an end in itself, and that can take some getting used to. It's worth thinking about where chemistry fits into the big picture.
Chemistry World June 2008 Sarah Houlton	Breaking the rules The author finds out about some chemical tricks that can give a new drug the best possible odds of success
Chemistry World May 31, 2009 Nina Notman	The natural approach to winning at drug discovery High throughput drug screening is often described as a casino, with the odds stacked on the side of success as long as a big enough library is used.
Chemistry World March 2011	Column: In the pipeline Drug discovery is an inherently risky business. Derek Lowe tries to balance some of the risk equations
Chemistry World September 2007 Derek Lowe	Column: In the Pipeline Will Phase Zero trials actually help drug development?
Chemistry World August 2007 Derek Lowe	Opinion: In the Pipeline Process chemists just don't get the credit they deserve.
Chemistry World June 2011	Column: In the pipeline Chemists are human. Humans are hierarchical. Therefore...well, therefore, you'll find a number of different roles and levels for scientists in a drug company's labs. Here's a rough ordering, from least experienced to most.
Chemistry World November 30, 2012 Andy Extance	Chemists cull compounds using 'intuition' Medicinal chemists might be using far fewer parameters to choose candidate fragments for a screening collection than they think they do. Their choices can be mimicked based on just one or two properties, a team led by researchers at Swiss-headquarted pharmaceutical firm Novartis has found.
Chemistry World December 17, 2012 Patrick Walter	RSC acquires rights to Merck Index The Royal Society of Chemistry has acquired the rights to the 'bible' of chemistry, the Merck Index, familiar around the world to medicinal chemists and drug discovery scientists.
Chemistry World November 28, 2013	Put the chemistry back in medicinal chemistry Today, synthetic skill is valued and appreciated much less in medicinal chemistry than in chemical development, though it is equally important for both. Much of the blame lies with the mismeasurement of productivity.
Chemistry World November 2006 Yfke Hager	Careers: Heartfelt Chemistry After working in New Zealand, medicinal chemistry tempted Ashley Jarvis back to the UK. He now works in his dream field.
Bio-IT World September 2006 Kevin Davies	Pfizer's Global Survey of Pharmacological Space The pharma blends knowledge, computational chemistry and research informatics to build a unified database. Gathering all the data in one place offered greater control for indexing and data retrieval and management, enabling Pfizer scientists to perform global mapping.
Chemistry World July 2008 Kevin Rogers	What future for small molecule therapy? Pharmaceutical companies overlook bench chemists at their peril
Chemistry World June 15, 2009 Matt Wilkinson	Concert arranges billion dollar GSK deal US-based Concert Pharmaceuticals has inked its first commercialization deal granting GlaxoSmithKline access to six deuterium-modified drugs
Chemistry World July 22, 2015 Judy Hayler	The handbook of medicinal chemistry: principles and practice The handbook of medicinal chemistry: principles and practice guides the reader through the R&D process from target validation to late stage clinical trials, via a series of chapters written by individuals in industry and academia.
Chemistry World August 2008	Column: In the pipeline Problems develop when there are too few workhorse reactions, which may well generate compounds that are too similar to each other. Are we at that stage now?
Chemistry World December 2007 Derek Lowe	Column: In the Pipeline The challenge of biologics.
Chemistry World August 23, 2012 Simon Campbell	Protecting patients at all costs A new funding model is urgently required to deliver innovative medicines that meet the medical needs of the 21st century and contribute to economic growth.
Chemistry World July 2010	Column: In the pipeline Derek Lowe ponders the possibility of phosphatase inhibitors
Chemistry World September 2008 Derek Lowe	Column: In the pipeline The author remembers leaving the ivory towers of academe to trade 'unusual and beautiful' for 'useful'
Chemistry World October 2008 Derek Lowe	Column: In the pipeline The author seeks a cure for 'compound bloat'
Bio-IT World November 2006 Kevin Davies	Jubilant Curries Favor with BioPharma The explosion of drug discovery and development operations in India is epitomized by the success of several companies. Quietly building on a decade of experience in computational and bio-IT fields, JBL is rapidly pushing into a suite of drug discovery and development activities.
Bio-IT World November 14, 2003 Malorye Branca	Genomics Provides the Kick Inside New tools and business structures show signs of plumping early-stage pipelines.
Chemistry World March 2012	Column: In the pipeline Drug discovery requires experimentation, says Derek Lowe. But chemists can be reluctant to stray from the elements they know and love
Chemistry World December 2006 Derek Lowe	Opinion: In the Pipeline A look at the story behind the growing investment by western companies in medicinal chemistry research in China.
Chemistry World January 2011	Column: In the pipeline Some medicinal chemists can't get enough fluorines in their molecules. The love-hate relationship is explained.
Chemistry World June 23, 2015 Derek Lowe	Missing the target There are enzymes that no mustard has ever cut, to steal a phrase from science fiction author James Blish. Phosphatases, the flip side of kinase activity, are a perfect example.
Chemistry World October 2010	Column: In the pipeline Derek Lowe investigates the comeback combinatorial chemistry has made in the field of drug discovery
Chemistry World January 7, 2014 Derek Lowe	Is there a drug for that? One hears a lot about the concept of 'druggability' in pharmaceutical research. If that concept has any meaning (and it probably does), then the implication is that there must be such a thing as 'undruggability'. So what does that look like?
Chemistry World August 2009 Derek Lowe	Column: In the pipeline The author considers what makes a good looking drug molecule - and how beauty is in the eye of the beholder
Bio-IT World April 15, 2003 Mark D. Uehling	Target Elimination Industry and FDA scientists turn to databases, applications software, and laboratory chips to move the safest, most effective molecules into clinical trials.
Chemistry World March 2012	Lead-oriented synthesis Ian Churcher and Alan Nadin call for the development of more robust synthetic tools to improve small molecule survival rates in the perilous journey from lead to drug
Chemistry World February 8, 2006 Jon Evans	To Boldly go Where no Chemist Has Gone Before Studying the interactions between different molecular fragments is taking researchers to the uncharted regions of chemical space.
Bio-IT World June 17, 2004 John Garvey	Rational Decisions As companies in the computationally guided rational drug design sector mature, they should be more sure of the boundaries that surround their proprietary technologies.
Bio-IT World July 11, 2002 Kevin Davies	Counting the Cost of Drug Discovery Much of the trouble ensnaring the drug industry is blamed on the exorbitant cost of drug discovery. Tangible proof that the bio-IT revolution will economize drug discovery is emerging, but there is still a long way to go.
Chemistry World July 26, 2012 Derek Lowe	Screen shots You might not think that the makeup of a compound screening collection could set off many arguments, but there are a few issues there that will do the trick almost every time.
Chemistry World September 12, 2012 Jon Evans	Drawing maps to hunt for biological gold Pharmaceutical companies should pay more attention to traditional medicine, say UK researchers. This follows their discovery that genetically-similar plants have traditionally been used to treat the same conditions in widely separated parts of the world.
Chemistry World September 2009	Column: In the pipeline What's the most difficult therapeutic area for drug discovery? They're certainly not all created equal - or if they were, they have definitely diverged since then. The question can be narrowed down quite a bit.
Chemistry World December 8, 2006	Expert Guidance on Clinical Trial Safety Clinical trial design in the UK is due for a shake up following the recommendations of an expert group commissioned in light of a disastrous trial that left six subjects fighting for their lives.
Bio-IT World August 13, 2003 Wendy Wolfson	Orphan Drugs: For Love or Money? Entrepreneurs organize to work toward cures for rare 'orphan' diseases.
Pharmaceutical Executive February 1, 2006 Ron Feemster	Gene Logic: Rescue Squad One or two late-stage clinical failures can land promising drug candidates on the shelf. Forever? Maybe not. Gene Logic tests Big Pharma's dead drugs for hundreds of different targets.
The Motley Fool May 5, 2004 Brian Gorman	Albany Molecular Gets Out-Outsourced Albany Molecular Research, provider of chemistry services to biotech and pharmaceutical clients, is suffering from the loss of business to low-cost competitors overseas.
Chemistry World June 9, 2010	Chemistry at Sussex under threat again The department, which topped The Guardian's 2010 university league table for chemistry, is set to lose some 40 per cent of its faculty, according to Phil Parsons, head of organic chemistry at Sussex.
Chemistry World April 2011	Column: In the Pipeline If you look over the whole pharmacopeia, you'll see there are a lot of compounds that got their start as natural products.
Chemistry World June 2007 Derek Lowe	Opinion: In the Pipeline A medicinal chemist experienced in pre-clinical drug discovery sets the record straight about pharmaceutical patents on traditional medicines.
Chemistry World May 2009	Column: In the pipeline Derek Lowe considers what we think we know about how drugs work once we've taken them